Items where Author is "Kesselheim, Aaron S."

Number of items: 15.
  • Sales revenues for new therapeutic agents approved by the United States Food and Drug Administration from 1995 to 2014:a retrospective study. (2024) Wouters, Olivier J. and Kesselheim, Aaron S. and Kuha, Jouni and Luyten, Jeroen picture_as_pdf
  • Post-marketing requirements for cancer drugs approved by the European Medicines Agency, 2004-2014. (2022) Cherla, Avi and Mossialos, Elias and Salcher-Konrad, Maximilian and Kesselheim, Aaron S. and Naci, Huseyin picture_as_pdf
  • Coverage of new drugs in Medicare Part D. (2022) Naci, Huseyin and Kyriopoulos, Ilias-Ioannis and Feldman, William B. and Hwang, Thomas J. and Kesselheim, Aaron S. and Chandra, Amitabh picture_as_pdf
  • Price changes and within-class competition of cancer drugs in the USA and Europe:a comparative analysis. (2022) Vokinger, Kerstin N. and Hwang, Thomas J. and Carl, David L. and Laube, Yannic and Ludwig, Wolf Dieter and Naci, Huseyin and Kesselheim, Aaron S.
  • Assessment of coverage in England of cancer drugs qualifying for US food and drug administration accelerated approval. Cherla, Avi and Naci, Huseyin and Kesselheim, Aaron S. and Gyawali, Bishal and Mossialos, Elias picture_as_pdf
  • Characteristics of preapproval and postapproval studies for drugs granted accelerated approval by the US food and drug administration. Naci, Huseyin and Smalley, Katelyn R. and Kesselheim, Aaron S.
  • Characteristics of prior authorization policies for new drugs in Medicare Part D. Naci, Huseyin and Forrest, Robin and Zhai, Mike and Stofesky, Amanda R. and Kesselheim, Aaron S. picture_as_pdf
  • Decision making under uncertainty:comparing regulatory and health technology assessment reviews of medicines in the United States and Europe. Vreman, Rick A. and Naci, Huseyin and Goettsch, Wim G. and Mantel-Teeuwisse, Aukje K. and Schneeweiss, Sebastian G. and Leufkens, Hubert G.M. and Kesselheim, Aaron S. picture_as_pdf
  • Differential legal protections for biologics vs. small-molecule drugs in the US. Wouters, Olivier J. and Vogel, Matthew and Feldman, William B. and Beall, Reed F. and Kesselheim, Aaron S. and Tu, S. Sean picture_as_pdf
  • Generating comparative evidence on new drugs and devices before approval. Naci, Huseyin and Salcher-Konrad, Maximilian and Kesselheim, Aaron S. and Dr.rer.nat, Beate Wiesler and Rochaix, Lise and Redberg, Rita and Salanti, Georgia and Jackson, Emily and Garner, Sarah and Stroup, Scott and Cipriani, Andrea picture_as_pdf
  • Manufacturer revenue on inhalers after expiration of primary patents, 2000-2021. Feldman, William B. and Tu, S. Sean and Alhiary, Rasha and Kesselheim, Aaron S. and Wouters, Olivier J. picture_as_pdf
  • Producing and using timely comparative evidence on drugs:lessons from clinical trials for covid-19. Naci, Huseyin and Kesselheim, Aaron S. and Rttingen, John Arne and Salanti, Georgia and Vandvik, Per O. and Cipriani, Andrea description
  • Quantifying research and development expenditures in the drug industry. Wouters, Olivier J. and Kesselheim, Aaron S. picture_as_pdf
  • Specialty drugs:a distinctly American phenomenon. Naci, Huseyin and Kesselheim, Aaron S. picture_as_pdf
  • Trends in time to withdrawal and full approval of accelerated approval cancer drug indications (1992–2024). Jenei, Kristina and Hahn, Georg and Kesselheim, Aaron S. and Tibau, Ariadna picture_as_pdf